Physician profile
John P Hakim
NPI 1730137688
$24,448.19
in general payments reported to CMS, 2019-2025
46 companies · $3,353 in 2025
The $3,353 reported for 2025 was more than what 89% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $1,384 · 2020: $1,463 · 2021: $2,181 · 2022: $4,205 · 2023: $9,007 · 2024: $2,856 · 2025: $3,353.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,648 · Consulting Fee: $6,604 · Travel and Lodging: $964.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,647.59 |
| Consulting Fee | $6,604.00 |
| Travel and Lodging | $964.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $11,287.24 | 2020-2025 | |
| Novo Nordisk INC | $1,693.14 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $1,467.74 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,253.87 | 2019-2025 | Farxiga, Lokelma, Wainua |
| Amgen INC. | $1,103.70 | 2020-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $855.77 | 2019-2025 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $812.02 | 2019-2025 | Jardiance |
| Esperion Therapeutics, INC. | $635.43 | 2020-2025 | Nexletol |
| Lilly USA, LLC | $601.99 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Actelion Pharmaceuticals US, INC. | $482.18 | 2019-2024 | Uptravi, Opsumit |
| Merck Sharp & Dohme LLC | $470.43 | 2021-2025 | Verquvo, Belsomra, Steglatro |
| Sanofi-Aventis U.S. LLC | $420.57 | 2019-2023 | |
| Pfizer INC. | $371.24 | 2020-2025 | |
| Scpharmaceuticals INC. | $336.17 | 2023-2025 | |
| Lexicon Pharmaceuticals, INC. | $284.11 | 2023-2024 | Inpefa |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $273.30 | 2020-2023 | Xarelto |
| Abbott Laboratories | $270.19 | 2019-2025 | Freestyle Libre 3, Thoratec Heartmate 3 Lvas Implant Kit |
| Alnylam Pharmaceuticals INC. | $215.24 | 2020-2025 | Amvuttra |
| Bridgebio Pharma, INC. | $203.34 | 2025 | Attruby |
| Boston Scientific Corporation | $178.96 | 2023-2024 | Mylux Patient Kit With Mobile Device, Lux-Dx Insertable Cardiac Monitor |
| Glaxosmithkline, LLC. | $146.69 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Dexcom, INC. | $138.49 | 2024-2025 | Dexcom G6 Transmitter |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $130.93 | 2019-2023 | Lifevest |
| Acadia Pharmaceuticals INC | $101.40 | 2025 | Nuplazid |
| Corvista Health, INC. | $71.08 | 2025 | Corvista System |
| Exact Sciences Corporation | $68.50 | 2025 | Cologuard Collection Kit |
| Arbor Pharmaceuticals, INC. | $61.86 | 2019-2022 | |
| Philips North America LLC | $56.80 | 2020-2025 | Mcot |
| Irhythm Technologies, INC. | $55.85 | 2019-2024 | Zio Xt Patch, Zio Monitor |
| Amarin Pharma, INC. | $43.35 | 2019-2020 | |
| Astrazeneca Uk Limited | $38.07 | 2019 | |
| Currax Pharmaceuticals LLC | $32.05 | 2021-2023 | Contrave |
| Edwards Lifesciences Corporation | $31.77 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Cmp Pharma, INC. | $31.16 | 2021 | |
| Mannkind Corporation | $30.83 | 2025 | |
| Kiniksa Pharmaceuticals, LTD. | $26.30 | 2023 | Arcalyst |
| Regeneron Healthcare Solutions, INC. | $24.90 | 2019 | |
| Heartflow, INC. | $24.45 | 2024 | |
| Medicomp INC | $21.11 | 2024 | Telepatch Cardiac Monitor |
| Kiniksa Pharmaceuticals International, Plc | $19.88 | 2024 | Arcalyst |
| Atricure, INC. | $18.93 | 2022 | |
| Kestra Medical Technology Services, INC. | $15.33 | 2023 | Assure Wcd |
| G Medical Diagnostic Services, INC. | $14.71 | 2022 | |
| Hikma Pharmaceuticals USA | $14.47 | 2022 | |
| Eisai INC. | $12.65 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$0.32 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Hakim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.